{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:05:20Z","timestamp":1778893520781,"version":"3.51.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.berh.2022.101791","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T18:32:45Z","timestamp":1667500365000},"page":"101791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Where is bone science taking us?"],"prefix":"10.1016","volume":"36","author":[{"given":"Bente L.","family":"Langdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 G.","family":"Uitterlinden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","article-title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis","volume":"234","author":"Tsuda","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib3","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"6656","key":"10.1016\/j.berh.2022.101791_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"issue":"6717","key":"10.1016\/j.berh.2022.101791_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.berh.2022.101791_bib7","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajhg.2008.06.015","article-title":"Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations","volume":"83","author":"Guerrini","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10.1016\/j.berh.2022.101791_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00223-019-00520-5","article-title":"Rare inherited forms of paget's disease and related syndromes","volume":"104","author":"Ralston","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"15","key":"10.1016\/j.berh.2022.101791_bib11","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa0810925","article-title":"Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin","volume":"361","author":"Riches","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","article-title":"Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys","volume":"49","author":"Ominsky","year":"2011","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.berh.2022.101791_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.berh.2022.101791_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115287","article-title":"Favorable skeletal benefit\/risk of long-term denosumab therapy: a virtual-twin analysis of fractures prevented relative to skeletal safety events observed","volume":"134","author":"Ferrari","year":"2020","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib18","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"16","key":"10.1016\/j.berh.2022.101791_bib20","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrendo.2015.71","article-title":"Short-term and long-term effects of osteoporosis therapies","volume":"11","author":"Reid","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib22","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib25","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.berh.2022.101791_bib26","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.berh.2022.101791_bib27","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1086\/515470","article-title":"Linkage of a gene causing high bone mass to human chromosome 11 (11q12- 13) [see comments]","volume":"60","author":"Johnson","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","author":"Little","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib29","first-page":"146","article-title":"Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13","volume":"59","author":"Gong","year":"1996","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-84-4-393","article-title":"The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals","volume":"84","author":"Beighton","year":"1976","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.berh.2022.101791_bib32","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/302416","article-title":"Localization of the gene for sclerosteosis to the van Buchem disease- gene region on chromosome 17q12-q21","volume":"64","author":"Balemans","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet"},{"issue":"20","key":"10.1016\/j.berh.2022.101791_bib34","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.berh.2022.101791_bib35","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev Cell"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"19","key":"10.1016\/j.berh.2022.101791_bib38","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2022.101791_bib39","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib40","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McCLung","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101791_bib42","first-page":"36","article-title":"Setrusumab for the treatment of osteogenesis imperfecta (OI): results from the phase IIb ASTEROID study","author":"Glorieux","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"16","key":"10.1016\/j.berh.2022.101791_bib43","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2022.101791_bib44","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jbmr.3439","article-title":"Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"15","key":"10.1016\/j.berh.2022.101791_bib45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2022.101791_bib46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","article-title":"Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study","volume":"81","author":"Chouinard","year":"2016","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/jbmr.3036","article-title":"Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Ominsky","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib48","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","article-title":"Cardiovascular safety and sclerostin inhibition","volume":"106","author":"Langdahl","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium","volume":"11","year":"1995","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.24296","article-title":"Novel PHEX gene locus-specific database: comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH)","volume":"43","author":"Sarafrazi","year":"2022","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","author":"Consortium","year":"2000","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib52","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031260","article-title":"Biology of fibroblast growth factor 23: from physiology to pathology","volume":"8","author":"Courbebaisse","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib53","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"issue":"21","key":"10.1016\/j.berh.2022.101791_bib54","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib55","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.berh.2022.101791_bib56","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101791_bib57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2019.04.005","article-title":"The genetic architecture of osteoporosis and fracture risk","volume":"126","author":"Trajanoska","year":"2019","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib58","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.845","article-title":"Genome-wide association identifies three new susceptibility loci for Paget's disease of bone","volume":"43","author":"Albagha","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.berh.2022.101791_bib59","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/ng.562","article-title":"Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone","volume":"42","author":"Albagha","year":"2010","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.berh.2022.101791_bib60","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/340731","article-title":"Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1\/p62) in Paget disease of bone","volume":"70","author":"Laurin","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"22","key":"10.1016\/j.berh.2022.101791_bib61","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1093\/hmg\/11.22.2735","article-title":"Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease","volume":"11","author":"Hocking","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.berh.2022.101791_bib62","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/jbmr.3964","article-title":"The loss of profilin 1 causes early onset paget's disease of bone","volume":"35","author":"Scotto di Carlo","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib63","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ajhg.2015.12.016","article-title":"ZNF687 mutations in severe Paget disease of bone associated with giant cell tumor","volume":"98","author":"Divisato","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/71667","article-title":"Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis","volume":"24","author":"Hughes","year":"2000","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","article-title":"Osteoprotegerin deficiency and juvenile Paget's disease","volume":"347","author":"Whyte","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.berh.2022.101791_bib66","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1359\/jbmr.2003.18.12.2095","article-title":"Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype","volume":"18","author":"Chong","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng1332","article-title":"Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein","volume":"36","author":"Watts","year":"2004","journal-title":"Nat Genet"},{"issue":"7442","key":"10.1016\/j.berh.2022.101791_bib68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature11922","article-title":"Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS","volume":"495","author":"Kim","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.berh.2022.101791_bib69","first-page":"10","article-title":"Epigenetic analysis of Paget's disease of bone identifies differentially methylated loci that predict disease status","author":"Diboun","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.berh.2022.101791_bib70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bone.2016.01.007","article-title":"Development of a molecular test of Paget's disease of bone","volume":"84","author":"Guay-B\u00e9langer","year":"2016","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.berh.2022.101791_bib71","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/jbmr.1975","article-title":"Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease","volume":"28","author":"Albagha","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.berh.2022.101791_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030689","article-title":"Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone","volume":"9","author":"Cronin","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.berh.2022.101791_bib73","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jbmr.5650060511","article-title":"Familial aggregation of Paget's disease of bone","volume":"6","author":"Siris","year":"1991","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00223-014-9904-1","article-title":"Clinical presentation of Paget's disease: evaluation of a contemporary cohort and systematic review","volume":"95","author":"Tan","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1016\/j.berh.2022.101791_bib75","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jbmr.3066","article-title":"Long-term randomized trial of intensive versus symptomatic management in paget's disease of bone: the PRISM-EZ study","volume":"32","author":"Tan","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1359\/jbmr.090709","article-title":"Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone","volume":"25","author":"Langston","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.berh.2022.101791_bib77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.2249","article-title":"Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture","volume":"44","author":"Estrada","year":"2012","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.berh.2022.101791_bib78","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/ng.3949","article-title":"Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis","volume":"49","author":"Kemp","year":"2017","journal-title":"Nat Genet"},{"issue":"7571","key":"10.1016\/j.berh.2022.101791_bib79","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature14878","article-title":"Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture","volume":"526","author":"Zheng","year":"2015","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002718","article-title":"Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus","volume":"8","author":"Medina-Gomez","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.berh.2022.101791_bib81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fendo.2019.00337","article-title":"Recent advances in the genetics of fractures in osteoporosis","volume":"10","author":"Koromani","year":"2019","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib82","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/annrheumdis-2017-212469","article-title":"Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density","volume":"77","author":"Alonso","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101791_bib83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2013.10.015","article-title":"Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus","volume":"59","author":"Oei","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.berh.2022.101791_bib84","doi-asserted-by":"crossref","first-page":"k3225","DOI":"10.1136\/bmj.k3225","article-title":"Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomisation study","volume":"362","author":"Trajanoska","year":"2018","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/17446651.2021.1924672","article-title":"Personalized fracture risk assessment: where are we at?","volume":"16","author":"Nguyen","year":"2021","journal-title":"Expet Rev Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbm4.10024","article-title":"Genetic risk factors for atypical femoral fractures (AFFs): a systematic review","volume":"2","author":"Nguyen","year":"2018","journal-title":"JBMR Plus"},{"issue":"18","key":"10.1016\/j.berh.2022.101791_bib87","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1056\/NEJMc1612804","article-title":"GGPS1 mutation and atypical femoral fractures with bisphosphonates","volume":"376","author":"Roca-Ayats","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2022.101791_bib88","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41574-021-00593-z","article-title":"The health effects of vitamin D supplementation: evidence from human studies","volume":"18","author":"Bouillon","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib89","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13148-021-01200-8","article-title":"Epigenome-wide association studies: current knowledge, strategies and recommendations","volume":"13","author":"Campagna","year":"2021","journal-title":"Clin Epigenet"},{"issue":"8","key":"10.1016\/j.berh.2022.101791_bib90","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/jbmr.3148","article-title":"Epigenome-wide association of DNA methylation in whole blood with bone mineral density","volume":"32","author":"Morris","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.berh.2022.101791_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/genes12081191","article-title":"Severity of idiopathic scoliosis is associated with differential methylation: an epigenome-wide association study of monozygotic twins with idiopathic scoliosis","volume":"12","author":"Carry","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.berh.2022.101791_bib92","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fbioe.2019.00364","article-title":"Whole-genome methylation analysis of phenotype discordant monozygotic twins reveals novel epigenetic perturbation contributing to the pathogenesis of adolescent idiopathic scoliosis","volume":"7","author":"Liu","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.berh.2022.101791_bib93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ebiom.2018.09.014","article-title":"Value of DNA methylation in predicting curve progression in patients with adolescent idiopathic scoliosis","volume":"36","author":"Meng","year":"2018","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib94","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00223-021-00924-2","article-title":"Role of the microbiome in regulating bone metabolism and susceptibility to osteoporosis","volume":"110","author":"Cronin","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib95","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11914-021-00675-x","article-title":"The gut microbiome: a new frontier in musculoskeletal research","volume":"19","author":"Li","year":"2021","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"10.1016\/j.berh.2022.101791_bib96","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/jbmr.1588","article-title":"The gut microbiota regulates bone mass in mice","volume":"27","author":"Sj\u00f6gren","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.berh.2022.101791_bib97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cellimm.2017.05.003","article-title":"Regulation of bone mass by the gut microbiota is dependent on NOD1 and NOD2 signaling","volume":"317","author":"Ohlsson","year":"2017","journal-title":"Cell Immunol"},{"issue":"6","key":"10.1016\/j.berh.2022.101791_bib98","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1172\/JCI86062","article-title":"Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics","volume":"126","author":"Li","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.berh.2022.101791_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/mSphereDirect.00545-17","article-title":"Microbiota reconstitution does not cause bone loss in germ-free mice","volume":"3","author":"Quach","year":"2018","journal-title":"mSphere"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib100","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1172\/JCI133473","article-title":"Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota","volume":"130","author":"Li","year":"2020","journal-title":"J Clin Invest"},{"issue":"47","key":"10.1016\/j.berh.2022.101791_bib101","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1607235113","article-title":"Gut microbiota induce IGF-1 and promote bone formation and growth","volume":"113","author":"Yan","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib102","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00223-004-0097-x","article-title":"Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia","volume":"75","author":"Pytlik","year":"2004","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib103","first-page":"433","article-title":"Effects of doxycycline on development of changes in histomorphometric parameters of bones induced by bilateral ovariectomy in rats","volume":"55","author":"Folwarczna","year":"2003","journal-title":"Pol J Pharmacol"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib104","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/joim.12805","article-title":"Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial","volume":"284","author":"Nilsson","year":"2018","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.berh.2022.101791_bib105","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2665-9913(19)30068-2","article-title":"Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"1","author":"Jansson","year":"2019","journal-title":"The Lancet Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2022.101791_bib106","doi-asserted-by":"crossref","first-page":"87","DOI":"10.12938\/bmfh.18-006","article-title":"Effect of Bacillus subtilis C-3102 on bone mineral density in healthy postmenopausal Japanese women: a randomized, placebo-controlled, double-blind clinical trial","volume":"37","author":"Takimoto","year":"2018","journal-title":"Biosci Microbiota Food Health"},{"issue":"7","key":"10.1016\/j.berh.2022.101791_bib107","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/07315724.2017.1318724","article-title":"Effects of a multispecies probiotic supplement on bone health in osteopenic postmenopausal women: a randomized, double-blind, controlled trial","volume":"36","author":"Jafarnejad","year":"2017","journal-title":"J Am Coll Nutr"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422200050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169422200050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:22:08Z","timestamp":1761499328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169422200050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S152169422200050X"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2022.101791","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Where is bone science taking us?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2022.101791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101791"}}